Dopamine and the Causes, Prevention, and Advanced Treatments of Parkinson’s Disease.
DOI:
https://doi.org/10.47611/jsrhs.v11i4.3392Keywords:
#Parkinson'sDisease, #MediteraneanDiet, #MRgFUS, #Vaccine, #Park-inShape, #ViralVectors, #DopamineAgonists, #GeneTherapy, #JeremyNashidAbstract
Parkinson's disease (PD) is a neurodegenerative disorder with a wide range of motor and non-motor symptoms. Despite optimal medical management, PD still results in a high disability rate and secondary complications, and many patients lead a sedentary lifestyle, which in turn is also associated with a higher co-morbidity and mortality. Dopamine is a type of monoamine neurotransmitter. It is made in your brain and acts as a chemical messenger, communicating messages between nerve cells in your brain and the rest of your body. Dopamine is what motivates us to do something. Dopamine is a large factor in many of our day-to-day actions: it decides our mood, what we remember, and even how we move and act. This Dopamine and PD study is anticipated to inform those with PD of treatments that work better than others. Strong elements of this research paper include treatments such as MR-Guided focused Ultrasound, Gene Therapy, Park-in-Shape, and the rise of a PD Vaccine. This research paper's secondary goal is to inform those looking to avoid PD or who already have PD and wish to avoid the symptoms on how to avoid the symptoms of the disease. This Dopamine and PD study aims to explain what dopamine is, how it works, how it affects the body, and the effects of unhealthy levels of dopamine.
Downloads
References or Bibliography
Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 681, Dopamine.
https://pubchem.ncbi.nlm.nih.gov/compound/Dopamine
Mishra A, Singh S, Shukla S. Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease. J Exp Neurosci. 2018 May 31;12:1179069518779829. doi: 10.1177/1179069518779829. PMID: 29899667; PMCID: PMC5985548.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985548/
Alexander GE. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004 Sep;6(3):259-80. doi: 10.31887/DCNS.2004.6.3/galexander. PMID: 22033559; PMCID: PMC3181806.
https://pubmed.ncbi.nlm.nih.gov/22033559/
Liu C, Kaeser PS. Mechanisms and regulation of dopamine release. Curr Opin Neurobiol. 2019 Aug;57:46-53. doi: 10.1016/j.conb.2019.01.001. Epub 2019 Feb 12. PMID: 30769276; PMCID: PMC6629510.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629510/
Nummenmaa, L., Seppälä, K., & Putkinen, V. (2020, March 6). Molecular imaging of the human emotion circuit. doi:10.31234/osf.io/5w63q
https://www.researchgate.net/publication/339755837_Molecular_imaging_of_the_human_emotion_circuit
Louise Morales-Brown, What is the connection between dopamine and Parkinson's disease?. Medical news today. 2021 June 1.
https://www.medicalnewstoday.com/articles/dopamine-parkinsons#parkinsons-disease
Cookson MR. alpha-Synuclein and neuronal cell death. Mol Neurodegener. 2009 Feb 4;4:9. doi: 10.1186/1750-1326-4-9. PMID: 19193223; PMCID: PMC2646729.
https://pubmed.ncbi.nlm.nih.gov/19193223/
Gasparini F, Di Paolo T, Gomez-Mancilla B. Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19. PMID: 23853735; PMCID: PMC3703788.
https://pubmed.ncbi.nlm.nih.gov/23853735/
Brian R Haas, Tessandra H Stewart, and Jing Zhang. Premotor biomarkers for Parkinson's disease - a promising direction of research.Transl Neurodegener. 2012; 1: 11. Published online 2012 May 31. doi: 10.1186/2047-9158-1-11
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514104/
Mónica Gómez-Benito, Noelia Granado, Patricia García-Sanz, Anne Michel, Mireille Dumoulin, and Rosario Moratalla. Modeling Parkinson’s Disease With the Alpha-Synuclein Protein.Front Pharmacol. 2020; 11: 356. Published online 2020 Apr 23. doi: 10.3389/fphar.2020.00356
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191035/
Thany SH, Reynier P, Lenaers G. Neurotoxicité des pesticides - Quel impact sur les maladies neurodégénératives ? [Neurotoxicity of pesticides: its relationship with neurodegenerative diseases]. Med Sci (Paris). 2013 Mar;29(3):273-8. French. doi: 10.1051/medsci/2013293013. Epub 2013 Mar 27. PMID: 23544381.
https://pubmed.ncbi.nlm.nih.gov/23544381/
Gramage E, Herradón G. Connecting Parkinson's disease and drug addiction: common players reveal unexpected disease connections and novel therapeutic approaches. Curr Pharm Des. 2011;17(5):449-61. doi: 10.2174/138161211795164103. PMID: 21375485.
https://pubmed.ncbi.nlm.nih.gov/21375485/
Haziq Kamal, Geok Chin Tan, Siti Fatimah Ibrahim,Mohd. Farooq Shaikh, Isa Naina Mohamed, Rashidi M. Pakri Mohamed, Adila A. Hamid, Azizah Ugusman and Jaya Kumar.Alcohol Use Disorder, Neurodegeneration, Alzheimer’s and Parkinson’s Disease: Interplay Between Oxidative Stress, Neuroimmune Response and Excitotoxicity.Front. Cell. Neurosci., 31 August 2020.Sec. Cellular Neuropathology. doi.org/10.3389/fncel.2020.00282
https://www.frontiersin.org/articles/10.3389/fncel.2020.00282/full
Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med. 2012 Jan;2(1):a008888. doi: 10.1101/cshperspect.a008888. PMID: 22315721; PMCID: PMC3253033.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253033/
Moon HE, Paek SH. Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol. 2015 Jun;24(2):103-16. doi: 10.5607/en.2015.24.2.103. Epub 2015 Jun 8. PMID: 26113789; PMCID: PMC4479806.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479806/
Rabiei Z, Solati K, Amini-Khoei H. Phytotherapy in treatment of Parkinson's disease: a review. Pharm Biol. 2019 Dec;57(1):355-362. doi: 10.1080/13880209.2019.1618344. PMID: 31141426; PMCID: PMC6542178.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542178/
Weiyao Yin MD, PhD,Marie Löf MD, PhD,Nancy L. Pedersen PhD,Sven Sandin PhD,Fang Fang MD, PhD. Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study. 20 October 2020.doi.org/10.1002/mds.28314
https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.28314
Devin K.Binder, Binit B.Shah, W. JeffreyElias. Focused ultrasound and other lesioning in the treatment of tremor. 15 April 2022, 120193. doi.org/10.1016/j.jns.2022.120193
https://www.sciencedirect.com/science/article/pii/S0022510X22000557
Pifl C, Kish SJ, Hornykiewicz O. Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov Disord. 2012 Nov;27(13):1618-24. doi: 10.1002/mds.25109. Epub 2012 Oct 4. PMID: 23038412; PMCID: PMC4533102.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533102/
Agrawal M, Garg K, Samala R, Rajan R, Naik V, Singh M. Outcome and Complications of MR Guided Focused Ultrasound for Essential Tremor: A Systematic Review and Meta-Analysis. Front Neurol. 2021 May 7;12:654711. doi: 10.3389/fneur.2021.654711. PMID: 34025558; PMCID: PMC8137896.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137896/
Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V,
Ma Y, Small M, Feigin A, During MJ, Kaplitt MG, Eidelberg D. Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity. Sci Transl Med. 2018 Nov 28;10(469):eaau0713. doi: 10.1126/scitranslmed.aau0713. PMID: 30487248.
https://pubmed.ncbi.nlm.nih.gov/30487248/
Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017 Aug;31(4):317-334. doi: 10.1007/s40259-017-0234-5. PMID: 28669112; PMCID: PMC5548848.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548848/
Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs. 2010 Mar;24(3):177-92. doi: 10.2165/11533740-000000000-00000. PMID: 20155994; PMCID: PMC2886503.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886503/
Benjamin Solomon, M.D.Gene Therapy. National Human Genome Research Institute. 2022 July 29. genome.gov/genetics-glossary/Gene-Therapy
https://www.genome.gov/genetics-glossary/Gene-Therapy
van der Kolk NM, Overeem S, de Vries NM, Kessels RP, Donders R, Brouwer M, Berg D, Post B, Bloem BR. Design of the Park-in-Shape study: a phase II double blind randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson's disease. BMC Neurol. 2015 Apr 16;15:56. doi: 10.1186/s12883-015-0312-6. PMID: 25880966; PMCID: PMC4418070.
https://pubmed.ncbi.nlm.nih.gov/25880966/
Kiran Yanamandra,Marina A. Gruden, Vida Casaite,Rolandas Meskys,Lars Forsgren,
Ludmilla A. Morozova-Roche.α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients. April 25, 2011. doi.org/10.1371/journal.pone.0018513.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018513
Sophie Holmes, PhD, Gerard Sanacora, MD, PhD. Using Ketamine to Treat Depression in Parkinson’s Disease. The Michael J.Fox foundation for Parkinson’s Research. 2021.
https://www.michaeljfox.org/grant/using-ketamine-treat-depression-parkinsons-disease
Published
How to Cite
Issue
Section
Copyright (c) 2022 Jeremy Nashid; Coach Jo
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
